Clinical trial of MBP8298 expands to
United States
View
or print this bulletin in its original format.
Medical Update Memo
January 24, 2007
SUMMARY
BioMS, an Edmonton-based biotechnology company,
has announced it has received permission from
the US Food and Drug Administration (FDA) to
carry out a phase III clinical trial of its
experimental drug MBP8298 as a potential treatment
for secondary-progressive MS. The study is
already underway in Canada, the United Kingdom,
Denmark and Sweden.
DETAILS
On January 19, BioMS, an Edmonton-based biotechnology
company, announced it has received permission
from the US Food and Drug Administration
(FDA) to carry out a phase III clinical trial
of its experimental drug MBP8298 as a potential
treatment for secondary-progressive MS. According
to the company, the randomized, double-blind
study will enrol approximately 510 people
with secondary-progressive MS who will receive
either MBP8298 or placebo intravenously (into
a vein) every six months for two years.
A phase II/III clinical trial of the use of
MBP8298 in the treatment of secondary-progressive
MS is already underway in Canada, the United
Kingdom, Denmark and Sweden. Approximately
550 participants will receive either MBP8298
or placebo intravenously every six months for
two years. BioMS, an Edmonton-based biotechnology
company, is sponsoring the study. For more
information about the study, see the BioMS
website: www.biomsmedical.com
MBP8298 is a synthetic peptide that corresponds
to a portion of the body’s own myelin
basic protein, one of the proteins that make
up myelin, the vital protective covering of
nerves in the central nervous system. This
sequence is thought to be the main target of
immune system cells during MS attacks. By administering
MBP8298, the researchers hope to restore immune
tolerance of this important myelin component.
For more details about the results of earlier
studies of MBP8298, see the medical update
memo, June 23, 2006, Small Edmonton-based clinical
trial shows some slowing of disease progression
on the MS Society website: www.mssociety.ca [key word search: MBP8298].
ASK MS Information System Code: 1.4.1.76.o
National Research Department
National Marketing and Communications Department
Back
to top
 |
